Vision
No one should die of cancer
Addressing the hallmarks of cancer lethality with
first-in-class ND-ADCs
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality and deliver safe and effective cancer therapies to all.
Mission
Exploiting novel biology to gain revolutionary power over cancer
Our Science
Our novel and first-in-class Nuclear- Delivered Antibody-Drug Conjugates™ (ND-ADCs) target an intracellular transporter called TM4SF1. TM4SF1 is highly expressed in the tumor micro- environment and carries proteins – and our antibodies – from the cell surface to the nucleus.
TM4SF1 has high expression across all solid tumors with a correlation to mortality. Expression is in both tumor cells and tumor vascular endothelium. Selective delivery to these cells may result in high therapeutic margin with little delivery to health tissue.
Exploiting the biology of TM4SF1 and the nuclear delivery of payloads may unlock exceptional efficacy through novel and potent mechanisms of action:
- Antiangiogenesis (regression of angiogenic tumor vasculature)
- Tumor cell killing (especially invasive and metastic tumor cells)
- Immune activation
Angiex’s lead ND-ADC, AGX101, will soon be heading to the clinic, and a pipeline of additional ND-ADCs is in discovery-stage development.
Our Values
Driven by science
We relentlessly pursue the truth, and embrace rigorous effort to uncover it. Our commitment to discovery surpasses personal and professional considerations.
Creative and courageous
We innovate boldly and pursue our mission relentlessly. No aim is too high, no detail is too low, and the right thing to do is never left undone.
Thoughtful vigor
We move with energy, yet with care and purpose. We act with speed not haste, and do things right the first time.
Love of neighbor
We are neighbor to cancer patients, neighbor to co-workers and shareholders, and labor to bring them good.
Leadership team
Extensive oncology drug development and commercialization experience
Iain Dukes
Executive Chairman
- Venture Partner, Orbimed Advisors
- Experienced CEO and Executive Chair
- Former SVP Business Development & Licensing at Merck and VP External R&D at Amgen
Paul Jaminet
, PhD
Founder & CEO
- Angiex founder. Raised $130M in capital in 3 companies
- Former co-founder & executive in software technology, digital media, finance, and health businesses
- PhD in Physics, University of California, Berkeley; Astrophysicist, Harvard-Smithsonian Center for Astrophysics
Glen Weiss
, MD, MBA
Chief Medical Officer
- Former VP of Clinical Sciences, SOTIO Biotech
- Former Director of Phase 1 Clinical Research, BIDMC, and faculty, Harvard Medical School
Shou-Ching Jaminet
, PHD
Founder, Scientific Adviser
- World’s leading expert in TM4SF1
- Former Director, MGTP Laboratory, BIDMC, and Member of Faculty, Harvard Medical School
Hal Dvorak
, MD
Founder, SAB Chair
- Discovered VEGF-A
- Mallinckrodt Distinguished Professor of Pathology emeritus, Harvard Medical School
Board of Directors
Iain Dukes
Angiex
Paul Jaminet
Angiex
Errik Anderson
Alloy Therapeutics
Jason Camm
Thiel Capital
Fabian Hansen
Presight Capital
Duan Xiang
Fontus Capital
